Shingrix (Herpes Zoster vaccine Recombinant, adjuvanted)

Product menu

Female older adult with shingles on forehead

A quarter of people in the UK are estimated to develop shingles in their lifetime.1

Patients become eligible for shingles vaccination every month: identify and vaccinate your older adults and severely immunocompromised patients as soon as they qualify.

Why wait?

Take action to help protect your patients from shingles as soon as they become eligible.

Help to reduce the burden of shingles on your patients and practice through effective implementation of the Shingles National Immunisation Programme

Shingles is a painful disease that can have serious and long-lasting complications in some patients2,3

Explore the impact of shingles

Take a consistent and proactive approach to implementing the Shingles National Immunisation Programme to help protect your patients in a way that is manageable for your practice

SHINGRIX is given according to a 2-dose vaccination schedule. Please refer to official local guidance for second dose administration. This may differ from the Shingrix SPC. Ensure that your patients complete the full 2-dose vaccination course to maximise the protection offered against shingles.4

Since 1st September 2025, eligibility for shingles vaccination expands to include all severely immunocompromised individuals aged 18 years old and over with no upper age limit (as defined by the Green Book chapter on shingles).1,5

NA

As of 1st September 2025, the eligible cohorts for the Shingles National Immunisation Programme in England & Wales are:

  • Individuals aged ≥ 18 years who are severely immunocompromised (as defined in the Green Book)
    • There is no upper age limit for this cohort 
  • Individuals who turned 65 years old on or after 1st September 2023
    • Those born before 1st September 1958 will become eligible when they turn 70 years old
    • Remain eligible until their 80th birthday
  • Individuals aged 70-79 years old
    • Remain eligible until their 80th birthday

Note: In Wales, if an individual is already 65 years or older but not yet 80 years old, General Practices can provide the vaccine opportunistically if possible.

NA

As of 1st September 2025, the eligible cohorts for the Shingles National Immunisation Programme in Northern Ireland & Scotland are:

  • Individuals aged ≥ 18 years old who are severely immunocompromised (as defined in the Green Book)
    • There is no upper age limit for this cohort
  • Individuals who turned 65 on 1st September each year or individuals who were 65 years of age on 1st September 2023 remain eligible until they turn 80
    • Those born before 2nd Sept 1957 will be eligible when they are 70 years of age on the 1st September
    • Individuals aged 70-79 years.They remain eligible until they turn 80 years old

Visit our implementation page for links to helpful resources that support the delivery of the Shingles National Immunisation Programme

Explore Implementation Resources

SHINGRIX: effective long-term shingles protection, achieved with two doses.4,11-13

SHINGRIX Overview

Prescribing information (UK)

Download

Summary of product characteristics (UK)

open

References

  1. UKHSA Green Book: Shingles (herpes zoster): the green book chapter. August 2025 chapter.
  2. UK NICE Clinical Knowledge Summaries, 2026. Shingles: What are the complications?
  3. UK NICE Clinical Knowledge Summaries, 2026. Shingles:What are the clinical features of shingles?
  4. SHINGRIX Summary of Product Characteristics (United Kingdom)
  5. UK Health Security Agency. Shingles vaccination programme: expansion of Shingrix vaccine eligibility to all those who are severely immunosuppressed and aged 18 years and over. Published July 2025
  6. Public Health Wales. Shingles – Information for health professionals.
  7. Shingles Immunisation Eligible groups – Public Health Scotland.
  8. Shingles Vaccination Programme 2025-26 SGHD CMO (2025) Chief Medical Officer for Scotland. Accessed 29th January 2026
  9. Administration of shingles (herpes zoster) vaccine (recombinant, adjuvanted) Shingrix® - PGD Scot - Accessed 29th January 2026.
  10. Shingles Vaccination Programme 2025/2026 – Department of Health Northern Ireland
  11. Lal H, Cunningham A, Godeaux O, et al. N Engl J Med 2015;3722(22): 2087-2096.
  12. Cunningham AL, Lal H, Kovac M, et al. N Engl J Med 2016; 375(11): 1019-1032.
  13. Strezova A, Díez Domingo J, Cunningham AL, et al. eClinical Medicine 2025; 83: 103241

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2026 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

September 2026 | PM-GB-SGX-WCNT-230004 (V9.0)